GlycoMimetics Historical Income Statement

GLYC Stock

USD 0.35 0.04 12.90%

Historical analysis of GlycoMimetics income statement accounts such as Total Revenue of 9.5 K or Gross Profit of 9.5 K can show how well GlycoMimetics performed in making a profits. Evaluating GlycoMimetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of GlycoMimetics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining GlycoMimetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlycoMimetics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

About GlycoMimetics Income Statement Analysis

GlycoMimetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to GlycoMimetics shareholders. The income statement also shows GlycoMimetics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

GlycoMimetics Income Statement Chart

At present, GlycoMimetics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 41.2 M, whereas Total Revenue is forecasted to decline to 9,500.

Other Operating Expenses Research Development Ebitda Total Operating Expenses Total Other Income Expense Net Non Operating Income Net Other

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of GlycoMimetics. It is also known as GlycoMimetics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from GlycoMimetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into GlycoMimetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.At present, GlycoMimetics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 41.2 M, whereas Total Revenue is forecasted to decline to 9,500.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	264.6K	207.1K	175.7K	198.4K
Interest Income	19.8K	714.5K	2.2M	1.3M

Reconciled Depreciation Interest Income

GlycoMimetics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Reconciled Depreciation	Net Interest Income	Selling And Marketing Expenses
Depreciation And Amortization		0.0	-0.19	-0.31	0.91	-0.88	-0.88	0.93	-0.88	-0.39	0.91	-0.88	0.51	-0.72	0.05	0.7	-0.85	0.75	0.52	0.12	-0.4	-0.03
Interest Expense	0.0		-0.42	-0.36	0.17	-0.26	-0.26	0.0	-0.27	-0.39	0.17	-0.25	0.41	-0.42	0.46	0.56	-0.25	0.54	0.27	-0.97	-0.43	-0.79
Total Revenue	-0.19	-0.42		0.93	-0.19	0.45	0.45	-0.1	0.45	0.54	-0.19	0.45	-0.31	0.47	-0.25	-0.37	0.44	-0.52	-0.27	0.4	0.27	0.31
Gross Profit	-0.31	-0.36	0.93		-0.32	0.58	0.58	-0.26	0.58	0.6	-0.32	0.57	-0.51	0.54	-0.19	-0.43	0.57	-0.6	-0.49	0.3	0.18	0.27
Other Operating Expenses	0.91	0.17	-0.19	-0.32		-0.96	-0.96	0.98	-0.96	-0.47	1.0	-0.96	0.53	-0.83	0.15	0.86	-0.95	0.81	0.54	-0.06	-0.62	-0.09
Operating Income	-0.88	-0.26	0.45	0.58	-0.96		1.0	-0.92	1.0	0.59	-0.96	1.0	-0.61	0.89	-0.19	-0.87	0.99	-0.88	-0.61	0.15	0.59	0.17
Ebit	-0.88	-0.26	0.45	0.58	-0.96	1.0		-0.92	1.0	0.59	-0.96	1.0	-0.61	0.89	-0.19	-0.87	0.99	-0.88	-0.61	0.15	0.59	0.17
Research Development	0.93	0.0	-0.1	-0.26	0.98	-0.92	-0.92		-0.92	-0.41	0.98	-0.92	0.51	-0.75	0.03	0.74	-0.91	0.72	0.52	0.13	-0.53	-0.02
Ebitda	-0.88	-0.27	0.45	0.58	-0.96	1.0	1.0	-0.92		0.59	-0.96	1.0	-0.61	0.89	-0.19	-0.87	0.99	-0.88	-0.61	0.15	0.59	0.17
Cost Of Revenue	-0.39	-0.39	0.54	0.6	-0.47	0.59	0.59	-0.41	0.59		-0.47	0.57	-0.55	0.54	-0.19	-0.53	0.63	-0.8	-0.53	0.3	0.47	0.3
Total Operating Expenses	0.91	0.17	-0.19	-0.32	1.0	-0.96	-0.96	0.98	-0.96	-0.47		-0.96	0.53	-0.83	0.15	0.86	-0.95	0.81	0.54	-0.06	-0.62	-0.09
Income Before Tax	-0.88	-0.25	0.45	0.57	-0.96	1.0	1.0	-0.92	1.0	0.57	-0.96		-0.57	0.89	-0.2	-0.88	0.99	-0.87	-0.57	0.14	0.61	0.14
Total Other Income Expense Net	0.51	0.41	-0.31	-0.51	0.53	-0.61	-0.61	0.51	-0.61	-0.55	0.53	-0.57		-0.42	-0.04	0.49	-0.58	0.69	0.97	-0.28	0.03	-0.46
Net Income	-0.72	-0.42	0.47	0.54	-0.83	0.89	0.89	-0.75	0.89	0.54	-0.83	0.89	-0.42		-0.62	-0.88	0.88	-0.79	-0.43	0.3	0.68	0.08
Income Tax Expense	0.05	0.46	-0.25	-0.19	0.15	-0.19	-0.19	0.03	-0.19	-0.19	0.15	-0.2	-0.04	-0.62		0.38	-0.19	0.22	-0.03	-0.4	-0.4	0.09
Selling General Administrative	0.7	0.56	-0.37	-0.43	0.86	-0.87	-0.87	0.74	-0.87	-0.53	0.86	-0.88	0.49	-0.88	0.38		-0.85	0.86	0.47	-0.5	-0.72	-0.3
Net Income From Continuing Ops	-0.85	-0.25	0.44	0.57	-0.95	0.99	0.99	-0.91	0.99	0.63	-0.95	0.99	-0.58	0.88	-0.19	-0.85		-0.88	-0.58	0.14	0.63	0.15
Non Operating Income Net Other	0.75	0.54	-0.52	-0.6	0.81	-0.88	-0.88	0.72	-0.88	-0.8	0.81	-0.87	0.69	-0.79	0.22	0.86	-0.88		0.64	-0.44	-0.59	-0.45
Interest Income	0.52	0.27	-0.27	-0.49	0.54	-0.61	-0.61	0.52	-0.61	-0.53	0.54	-0.57	0.97	-0.43	-0.03	0.47	-0.58	0.64		-0.16	0.1	-0.26
Reconciled Depreciation	0.12	-0.97	0.4	0.3	-0.06	0.15	0.15	0.13	0.15	0.3	-0.06	0.14	-0.28	0.3	-0.4	-0.5	0.14	-0.44	-0.16		0.39	0.75
Net Interest Income	-0.4	-0.43	0.27	0.18	-0.62	0.59	0.59	-0.53	0.59	0.47	-0.62	0.61	0.03	0.68	-0.4	-0.72	0.63	-0.59	0.1	0.39		0.26
Selling And Marketing Expenses	-0.03	-0.79	0.31	0.27	-0.09	0.17	0.17	-0.02	0.17	0.3	-0.09	0.14	-0.46	0.08	0.09	-0.3	0.15	-0.45	-0.26	0.75	0.26

Click cells to compare fundamentals

GlycoMimetics Account Relationship Matchups

GlycoMimetics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	279.2K	270.8K	264.6K	207.1K	153.3K	217.6K
Total Revenue	9M	10.2M	1.2M	74.9K	10K	9.5K
Gross Profit	(899.3K)	10.2M	1.2M	74.9K	10K	9.5K
Other Operating Expenses	61.4M	61.7M	64.6M	47.5M	39.3M	41.2M
Operating Income	(61.4M)	(51.5M)	(63.4M)	(47.4M)	(39.3M)	(41.2M)
Ebit	(61.4M)	(51.5M)	(63.4M)	(47.4M)	(39.3M)	(41.2M)
Research Development	47.0M	44.9M	47.5M	28.4M	20.1M	29.5M
Ebitda	(61.1M)	(51.2M)	(63.2M)	(47.2M)	(39.1M)	(41.1M)
Total Operating Expenses	61.4M	61.7M	64.6M	47.5M	39.3M	41.2M
Income Before Tax	(57.9M)	(51.0M)	(63.4M)	(46.7M)	(36.9M)	(38.7M)
Total Other Income Expense Net	3.5M	482K	20K	715K	2.4M	2.5M
Net Income	(54.1M)	(50.3M)	(63.1M)	(93.3M)	(36.9M)	(38.7M)
Income Tax Expense	(3.8M)	(752.8K)	(284.6K)	46.6M	(637.0)	(605.15)
Selling General Administrative	14.4M	16.7M	17.1M	19.1M	19.2M	13.3M
Net Income Applicable To Common Shares	(57.9M)	(51.0M)	(63.4M)	(46.7M)	(42.0M)	(44.1M)
Net Income From Continuing Ops	(57.9M)	(51.0M)	(63.4M)	(46.7M)	(38.1M)	(40.0M)
Interest Income	3.5M	482K	19.8K	714.5K	2.2M	1.3M
Reconciled Depreciation	279.2K	270.8K	264.6K	207.1K	175.7K	198.4K
Net Interest Income	3.5M	482K	19.8K	714.5K	2.2M	1.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:

How To Invest In GlycoMimetics

Details

Is GlycoMimetics Stock a good investment?

Details

What is GlycoMimetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.62)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.59)

Return On Equity

(1.04)

The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlycoMimetics Historical Income Statement

About GlycoMimetics Income Statement Analysis

GlycoMimetics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

GlycoMimetics income statement Correlations

GlycoMimetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlycoMimetics income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit

Reconciled Depreciation	- 0.97	Interest Expense
Income Before Tax	- 0.96	Total Operating Expenses
Total Operating Expenses	- 0.96	Ebitda
Total Operating Expenses	- 0.96	Ebit
Total Operating Expenses	- 0.96	Operating Income
Income Before Tax	- 0.96	Other Operating Expenses